Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHIKV vaccine
- Development stage
- Preclinical
- Lead developer
- SVF Vaccines
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
CHIKV vaccine is an investigational vaccine candidate currently in preclinical development by SVF Vaccines for the prevention of Chikungunya virus infection. The vaccine is built on a proprietary dual platform that utilizes both DNA and mRNA technologies. This approach is designed to leverage the complementary strengths of both nucleic acid modalities to induce a robust and durable immune response, including the production of neutralizing antibodies and the activation of cellular immunity (T-cell response). By optimizing antigen expression through this hybrid delivery system, the vaccine aims to provide effective protection against the Chikungunya virus, a mosquito-borne alphavirus. As of early 2024, the program remains in the preclinical stage of development.
- Other names
- chikungunya vaccineSVF Vaccines chikungunya vaccine
Beyond the preview
Go deeper on CHIKV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHIKV vaccine.